Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Pick a track — progress rings update as you complete lessons.
9 lessons
9mMariTide is the once-monthly obesity candidate people keep comparing to weekly GLP-1s. Here's the Phase 2 dosing map — 140 / 280 / 420 mg and the escalation arms that mattered for tolerability.
7mMonthly conjugates can pack a bigger post-dose GI window. Here's how to think about MariTide tolerability using Phase 2 lessons — without fear content.
7mPetrelintide is the amylin analog drawing attention for tolerability. This beginner guide covers what it is, what ZUPREME-1 showed, and what to watch next.
8mPetrelintide is the Roche/Zealand once-weekly amylin analog drawing GLP-1-level attention for tolerability. Here's the Phase 2 dosing pattern, results, and what to track.
7mWeekly amylin agonists are not MOTS-c. Here's when to inject eloralintide for tolerability — dose-day meals, evening vs morning, and what to log.
8mTwo weekly amylin programs, two sponsors, two data shapes. Here's a clear eloralintide vs petrelintide comparison for people following the next obesity wave.
8mSearching for eloralintide dosage? Here is the clean map of Phase 2 once-weekly doses, titration arms, and weight-loss results — framed as clinical education, not a DIY protocol.
7mAmylin agonists can feel GLP-1-like in the gut. Here's how to think about eloralintide tolerability, escalation, and symptom tracking without turning trial data into fear content.
The new TRIUMPH-1 readout gives retatrutide users a clearer dose-response map: 4 mg, 9 mg, and 12 mg all worked, but the tolerability tradeoffs matter.
Also available at /blog for legacy links.